GLP1R and obesity due to melanocortin 4 receptor deficiency: GLP-1 RAs, such as semaglutide and tirzepatide, demonstrated consistent benefits across both obese and nonobese populations while addressing concerns about rapid or excessive weight loss, which could undermine the hemodynamic and survival advantages linked to obesity.